This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Long-term renal survival of γ3-heavy chain deposition disease: a case report
BMC Nephrology Open Access 17 July 2017
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lin J, Markowitz GS, Valeri AM, Kambham N, Sherman WH, Appel GB et al. Renal monoclonal immunoglobulin deposition disease: the disease spectrum. J Am Soc Nephrol 2001; 12: 1482–1492.
Pozzi C, D’Amico M, Fogazzi GB, Curioni S, Ferrario F, Pasquali S et al. Light chain deposition disease with renal involvement: clinical characteristic and prognostic factors. Am J Kidney Dis 2003; 42: 1154–1163.
Buxbaum JN, Genega EM, Lazowski P, Kumar A, Tunick PA, Kronzon I et al. Infiltrative non amyloidotic monoclonal immunoglobulin light chain cardiomyopathy: an underappreciated manifestation of plasma cell dyscrasias. Cardiology 2000; 93: 200–228.
Croitoru AG, Hytiroglou P, Schwartz ME, Saxena R . Liver transplantation for liver rupture due to light chain deposition disease: a case report. Semin Liver Dis 2006; 26: 298–303.
Hassoun H, Flombaum C, D’Agati VD, Rafferty BT, Cohen A, Klimek VM et al. High dose melphalan and auto SCT in patients with monoclonal Ig deposition disease. Bone Marr Transpl 2008; 42: 405–412.
Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR et al. Long-term outcome of autologous stem cell transplantation in light chain deposition disease. Nephrol Dial Transpl 2008; 23: 2052–2057.
Bladé J, Samson D, Reece D, Apperley J, Björkstrand B, Gahrton G et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998; 102: 1115–1123.
Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18–22 April 2004. Am J Hematol 2005; 79: 319–328.
Dember LM, Sanchorawala V, Seldin DC, Wright DG, LaValley M, Berk JL et al. Effect of dose-intensive intravenous melphalan and autologous blood stem-cell transplantation on AL amyloidosis-associated renal disease. Ann Intern Med 2001; 134: 746–753.
Kastris E, Migkou M, Gavriatopoulou M, Zirogiannis P, Hadjikonstantinou V, Dimopoulos MA . Treatment of light chain deposition disease with bortezomib and dexamethasone. Haematologica 2009; 94: 300–302.
Acknowledgements
This work was supported in part by Università di Bologna, Ricerca Fondamentale Orientata (MC), BolognAIL and Fondazione Del Monte.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Brioli, A., Zamagni, E., Pasquali, S. et al. Long-term follow-up after autologous stem cell transplantation for light- and heavy-chain deposition disease. Bone Marrow Transplant 47, 1248–1249 (2012). https://doi.org/10.1038/bmt.2011.252
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2011.252
This article is cited by
-
Long-term renal survival of γ3-heavy chain deposition disease: a case report
BMC Nephrology (2017)